These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 38291516)

  • 21. CCL21-DC in situ vaccination in murine NSCLC overcomes resistance to immunotherapy and generates systemic tumor-specific immunity.
    Salehi-Rad R; Lim RJ; Du Y; Tran LM; Li R; Ong SL; Ling Huang Z; Dumitras C; Zhang T; Park SJ; Crosson W; Kahangi B; Abascal J; Seet C; Oh M; Shabihkhani M; Paul M; Krysan K; Lisberg AE; Garon EB; Liu B; Dubinett SM
    J Immunother Cancer; 2023 Sep; 11(9):. PubMed ID: 37730274
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Glutaminase inhibition impairs CD8 T cell activation in STK11-/Lkb1-deficient lung cancer.
    Best SA; Gubser PM; Sethumadhavan S; Kersbergen A; Negrón Abril YL; Goldford J; Sellers K; Abeysekera W; Garnham AL; McDonald JA; Weeden CE; Anderson D; Pirman D; Roddy TP; Creek DJ; Kallies A; Kingsbury G; Sutherland KD
    Cell Metab; 2022 Jun; 34(6):874-887.e6. PubMed ID: 35504291
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Targeting the ERβ/HER Oncogenic Network in
    Almotlak AA; Farooqui M; Soloff AC; Siegfried JM; Stabile LP
    Int J Mol Sci; 2021 Dec; 23(1):. PubMed ID: 35008514
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Characteristics of the immune microenvironment and their clinical significance in non-small cell lung cancer patients with ALK-rearranged mutation.
    Zhang B; Zeng J; Zhang H; Zhu S; Wang H; He J; Yang L; Zhou N; Zu L; Xu X; Song Z; Xu S
    Front Immunol; 2022; 13():974581. PubMed ID: 36159860
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Stromal reprogramming overcomes resistance to RAS-MAPK inhibition to improve pancreas cancer responses to cytotoxic and immune therapy.
    Liu X; Baer JM; Stone ML; Knolhoff BL; Hogg GD; Turner MC; Kao YL; Weinstein AG; Ahmad F; Chen J; Schmidt AD; Klomp JA; Coho H; Coho KS; Coma S; Pachter JA; Bryant KL; Kang LI; Lim KH; Beatty GL; DeNardo DG
    Sci Transl Med; 2024 Oct; 16(770):eado2402. PubMed ID: 39441902
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dissecting the clinicopathologic, genomic, and immunophenotypic correlates of KRAS
    Ricciuti B; Alessi JV; Elkrief A; Wang X; Cortellini A; Li YY; Vaz VR; Gupta H; Pecci F; Barrichello A; Lamberti G; Nguyen T; Lindsay J; Sharma B; Felt K; Rodig SJ; Nishino M; Sholl LM; Barbie DA; Negrao MV; Zhang J; Cherniack AD; Heymach JV; Meyerson M; Ambrogio C; Jänne PA; Arbour KC; Pinato DJ; Skoulidis F; Schoenfeld AJ; Awad MM; Luo J
    Ann Oncol; 2022 Oct; 33(10):1029-1040. PubMed ID: 35872166
    [TBL] [Abstract][Full Text] [Related]  

  • 27. KRAS G12D mutation predicts lower TMB and drives immune suppression in lung adenocarcinoma.
    Gao G; Liao W; Ma Q; Zhang B; Chen Y; Wang Y
    Lung Cancer; 2020 Nov; 149():41-45. PubMed ID: 32956987
    [TBL] [Abstract][Full Text] [Related]  

  • 28. RANKL Signaling Sustains Primary Tumor Growth in Genetically Engineered Mouse Models of Lung Adenocarcinoma.
    Faget J; Contat C; Zangger N; Peters S; Meylan E
    J Thorac Oncol; 2018 Mar; 13(3):387-398. PubMed ID: 29223537
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Inactivation of AMPK Leads to Attenuation of Antigen Presentation and Immune Evasion in Lung Adenocarcinoma.
    Gao Y; Päivinen P; Tripathi S; Domènech-Moreno E; Wong IPL; Vaahtomeri K; Nagaraj AS; Talwelkar SS; Foretz M; Verschuren EW; Viollet B; Yan Y; Mäkelä TP
    Clin Cancer Res; 2022 Jan; 28(1):227-237. PubMed ID: 34667030
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cryoablation triggers type I interferon-dependent antitumor immunity and potentiates immunotherapy efficacy in lung cancer.
    Gu C; Wang X; Wang K; Xie F; Chen L; Ji H; Sun J
    J Immunother Cancer; 2024 Jan; 12(1):. PubMed ID: 38272564
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Targeting integrin α5 in fibroblasts potentiates colorectal cancer response to PD-L1 blockade by affecting extracellular-matrix deposition.
    Lu L; Gao Y; Huang D; Liu H; Yin D; Li M; Zheng J; Wang S; Wu W; Zhao L; Bi D; Zhang Y; Song F; Xie R; Wang J; Qin H; Wei Q
    J Immunother Cancer; 2023 Dec; 11(12):. PubMed ID: 38040421
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Id1 and PD-1 Combined Blockade Impairs Tumor Growth and Survival of
    Baraibar I; Roman M; Rodríguez-Remírez M; López I; Vilalta A; Guruceaga E; Ecay M; Collantes M; Lozano T; Alignani D; Puyalto A; Oliver A; Ortiz-Espinosa S; Moreno H; Torregrosa M; Rolfo C; Caglevic C; García-Ros D; Villalba-Esparza M; De Andrea C; Vicent S; Pío R; Lasarte JJ; Calvo A; Ajona D; Gil-Bazo I
    Cancers (Basel); 2020 Oct; 12(11):. PubMed ID: 33126649
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Trametinib sensitizes KRAS-mutant lung adenocarcinoma tumors to PD-1/PD-L1 axis blockade via Id1 downregulation.
    Puyalto A; Rodríguez-Remírez M; López I; Macaya I; Guruceaga E; Olmedo M; Vilalta-Lacarra A; Welch C; Sandiego S; Vicent S; Valencia K; Calvo A; Pio R; Raez LE; Rolfo C; Ajona D; Gil-Bazo I
    Mol Cancer; 2024 Apr; 23(1):78. PubMed ID: 38643157
    [TBL] [Abstract][Full Text] [Related]  

  • 34. ETS1 regulates Twist1 transcription in a Kras
    Millien G; Cao Y; O'Hara CJ; Tagne JB; Hinds A; Williams MC; Ramirez MI; Kathuria H
    Clin Exp Metastasis; 2018 Mar; 35(3):149-165. PubMed ID: 29909489
    [TBL] [Abstract][Full Text] [Related]  

  • 35. LKB1 and KEAP1/NRF2 Pathways Cooperatively Promote Metabolic Reprogramming with Enhanced Glutamine Dependence in
    Galan-Cobo A; Sitthideatphaiboon P; Qu X; Poteete A; Pisegna MA; Tong P; Chen PH; Boroughs LK; Rodriguez MLM; Zhang W; Parlati F; Wang J; Gandhi V; Skoulidis F; DeBerardinis RJ; Minna JD; Heymach JV
    Cancer Res; 2019 Jul; 79(13):3251-3267. PubMed ID: 31040157
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inhibition of Granulocytic Myeloid-Derived Suppressor Cells Overcomes Resistance to Immune Checkpoint Inhibition in LKB1-Deficient Non-Small Cell Lung Cancer.
    Li R; Salehi-Rad R; Crosson W; Momcilovic M; Lim RJ; Ong SL; Huang ZL; Zhang T; Abascal J; Dumitras C; Jing Z; Park SJ; Krysan K; Shackelford DB; Tran LM; Liu B; Dubinett SM
    Cancer Res; 2021 Jun; 81(12):3295-3308. PubMed ID: 33853830
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Metformin Enhances Cisplatin-Induced Apoptosis and Prevents Resistance to Cisplatin in Co-mutated KRAS/LKB1 NSCLC.
    Moro M; Caiola E; Ganzinelli M; Zulato E; Rulli E; Marabese M; Centonze G; Busico A; Pastorino U; de Braud FG; Vernieri C; Simbolo M; Bria E; Scarpa A; Indraccolo S; Broggini M; Sozzi G; Garassino MC
    J Thorac Oncol; 2018 Nov; 13(11):1692-1704. PubMed ID: 30149143
    [TBL] [Abstract][Full Text] [Related]  

  • 38.
    Gu M; Xu T; Chang P
    Ther Adv Med Oncol; 2021; 13():17588359211006950. PubMed ID: 33995590
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Molecular heterogeneity of anti-PD-1/PD-L1 immunotherapy efficacy is correlated with tumor immune microenvironment in East Asian patients with non-small cell lung cancer.
    Jin R; Liu C; Zheng S; Wang X; Feng X; Li H; Sun N; He J
    Cancer Biol Med; 2020 Aug; 17(3):768-781. PubMed ID: 32944405
    [No Abstract]   [Full Text] [Related]  

  • 40. Clinical outcomes and immune phenotypes associated with
    Malhotra J; Ryan B; Patel M; Chan N; Guo Y; Aisner J; Jabbour SK; Pine S
    J Thorac Dis; 2022 Jun; 14(6):1772-1783. PubMed ID: 35813711
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.